

M Hasib Sidiqi

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7702637/m-hasib-sidiqi-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

60
papers

417
citations

13
h-index

19
g-index

68
ext. papers

562
ext. citations

4.3
avg, IF

3.71
L-index

| # | Paper | IF | Citations |
|----|---|-----|-----------|
| 60 | Imaging flow cytometry shows monosomy 17 in circulating plasma cells in myeloma.. <i>Pathology</i> , 2022 , | 1.6 | |
| 59 | Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous stem cell transplantation.. <i>Blood Cancer Journal</i> , 2022 , 12, 59 | 7 | 0 |
| 58 | Acute seizures and status epilepticus in immune effector cell associated neurotoxicity syndrome (ICANS).. <i>Blood Cancer Journal</i> , 2022 , 12, 62 | 7 | 0 |
| 57 | Long-term Outcomes of Sequential Hematopoietic Stem Cell Transplantation and Kidney Transplantation: Single-center Experience. <i>Transplantation</i> , 2021 , 105, 1615-1624 | 1.8 | |
| 56 | Characteristics and outcomes of therapy-related myeloid neoplasms following autologous stem cell transplantation for multiple myeloma. <i>Blood Cancer Journal</i> , 2021 , 11, 63 | 7 | 0 |
| 55 | Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021. <i>Blood Cancer Journal</i> , 2021 , 11, 90 | 7 | 6 |
| 54 | A randomized, open-label, phase 3 study of low-dose selinexor and lenalidomide (Len) versus len maintenance post autologous stem cell transplant (ASCT) for newly diagnosed multiple myeloma (NDMM): ALLG MM23, Sealand.. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS8055-TPS8055 | 2.2 | 1 |
| 53 | Prognostic value of NT-ProBNP and troponin T in patients with light chain amyloidosis and kidney dysfunction undergoing autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2021 , 56, 274-277 | 4.4 | 0 |
| 52 | Depth of response prior to autologous stem cell transplantation predicts survival in light chain amyloidosis. <i>Bone Marrow Transplantation</i> , 2021 , 56, 928-935 | 4.4 | 2 |
| 51 | Immune-mediated neuromuscular complications of graft-versus-host disease. <i>Muscle and Nerve</i> , 2021 , 63, 852-860 | 3.4 | 2 |
| 50 | Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trials. <i>American Journal of Hematology</i> , 2021 , 96, 1131-1136 | 7.1 | 6 |
| 49 | Comparison of the current renal staging, progression and response criteria to predict renal survival in AL amyloidosis using a Mayo cohort. <i>American Journal of Hematology</i> , 2021 , 96, 446-454 | 7.1 | 3 |
| 48 | Differences in engraftment with day-1 compared with day-2 melphalan prior to stem cell infusion in myeloma patients receiving autologous stem cell transplant. <i>Bone Marrow Transplantation</i> , 2020 , 55, 2132-2137 | 4.4 | 5 |
| 47 | Prognostic Role of Beta-2 Microglobulin in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 1402-1405 | 4.7 | 2 |
| 46 | The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?. <i>Blood Cancer Journal</i> , 2020 , 10, 52 | 7 | 4 |
| 45 | Venetoclax for the treatment of translocation (11;14) AL amyloidosis. <i>Blood Cancer Journal</i> , 2020 , 10, 55 | 7 | 22 |
| 44 | Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis. <i>American Journal of Hematology</i> , 2020 , 95, 497-502 | 7.1 | 27 |

| | | | |
|----|---|------|----|
| 43 | Trends in Outcomes in Australia and New Zealand in Autologous Stem Cell Transplantation in Older Patients with Multiple Myeloma: An Australasian Bone Marrow Transplant Recipient Registry Study. <i>Blood</i> , 2020 , 136, 11-12 | 2.2 | 0 |
| 42 | Differences in Clinical Presentation and Outcomes between Metropolitan and Rural Myeloma Patients. <i>Blood</i> , 2020 , 136, 44-45 | 2.2 | |
| 41 | Presence of Multiple High Risk Cytogenetic Abnormalities Is Associated with Rapid Progression and Shorter Survival in Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2020 , 136, 23-23 | 2.2 | |
| 40 | Depth of response prior to autologous stem cell transplantation to predict survival in light chain amyloidosis.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 8516-8516 | 2.2 | |
| 39 | Delayed neutrophil engraftment in patients receiving Daratumumab as part of their first induction regimen for multiple myeloma. <i>American Journal of Hematology</i> , 2020 , 95, E8-E10 | 7.1 | 5 |
| 38 | Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients. <i>American Journal of Hematology</i> , 2020 , 95, 4-9 | 7.1 | 6 |
| 37 | The Human Microbiota in Multiple Myeloma and Proteasome Inhibitors. <i>Acta Haematologica</i> , 2020 , 143, 118-123 | 2.7 | 7 |
| 36 | Joint Pain and Proteinuria. <i>JAMA - Journal of the American Medical Association</i> , 2019 , 322, 1512-1513 | 27.4 | 1 |
| 35 | Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 1520-1525 | 4.7 | 6 |
| 34 | Two types of amyloidosis presenting in a single patient: a case series. <i>Blood Cancer Journal</i> , 2019 , 9, 30 | 7 | 29 |
| 33 | Autologous stem cell transplantation in patients with AL amyloidosis with impaired renal function. <i>Bone Marrow Transplantation</i> , 2019 , 54, 1775-1779 | 4.4 | 5 |
| 32 | Daratumumab for the treatment of AL amyloidosis. <i>Leukemia and Lymphoma</i> , 2019 , 60, 295-301 | 1.9 | 20 |
| 31 | Plasma cell proliferative index post-transplant is a powerful predictor of prognosis in myeloma patients failing to achieve a complete response. <i>Bone Marrow Transplantation</i> , 2019 , 54, 442-447 | 4.4 | 5 |
| 30 | Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosis. <i>Blood Advances</i> , 2019 , 3, 1226-1229 | 7.8 | 3 |
| 29 | Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis. <i>American Journal of Hematology</i> , 2019 , 94, 1020-1026 | 7.1 | 25 |
| 28 | Improvement in Gastrointestinal Symptoms From Light Chain Amyloidosis After Adalimumab Therapy. <i>Mayo Clinic Proceedings</i> , 2019 , 94, 1380-1381 | 6.4 | |
| 27 | Impact of consolidation therapy post autologous stem cell transplant in patients with light chain amyloidosis. <i>American Journal of Hematology</i> , 2019 , 94, 1066-1071 | 7.1 | 9 |
| 26 | Characteristics and Outcomes of Therapy Related Myeloid Neoplasms in Patients with Multiple Myeloma Following Autologous Stem Cell Transplantation. <i>Blood</i> , 2019 , 134, 4560-4560 | 2.2 | 1 |

| | | | |
|----|--|-----|----|
| 25 | Peak Lymphocyte Count after CAR T Infusion Is a Clinically Accessible Test That Correlates with Clinical Response in Axicabtagene Ciloleucel Therapy for Lymphoma. <i>Blood</i> , 2019 , 134, 4106-4106 | 2.2 | 4 |
| 24 | Outcomes of patients with light chain amyloidosis who had autologous stem cell transplantation with three or more organs involved.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 8011-8011 | 2.2 | |
| 23 | Delayed Neutrophil Engraftment in Patients Receiving Daratumumab As Part of Their First Induction Regimen for Multiple Myeloma. <i>Blood</i> , 2019 , 134, 4505-4505 | 2.2 | |
| 22 | Patterns of Relapse and Treatment for Relapsed/Refractory AL Amyloidosis: A Systematic Review. <i>Blood</i> , 2019 , 134, 5556-5556 | 2.2 | |
| 21 | Optimal Therapy for Relapsed AL Amyloidosis Post Autologous Stem Cell Transplant. <i>Blood</i> , 2019 , 134, 3171-3171 | 2.2 | 0 |
| 20 | Monoclonal gammopathy plus positive amyloid biopsy does not always equal AL amyloidosis. <i>American Journal of Hematology</i> , 2019 , 94, E141-E143 | 7.1 | 13 |
| 19 | Autologous Stem Cell Transplant for IgM-Associated Amyloid Light-Chain Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, e108-e111 | 4.7 | 11 |
| 18 | Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2019 , 54, 1077-1081 | 4.4 | 3 |
| 17 | T-cell large granular lymphocytic leukemia and plasma cell disorders. <i>Haematologica</i> , 2019 , 104, e108-e110 | | 6 |
| 16 | Plasma cell proliferative index predicts outcome in immunoglobulin light chain amyloidosis treated with stem cell transplantation. <i>Haematologica</i> , 2018 , 103, 1229-1234 | 6.6 | 8 |
| 15 | Autologous Stem Cell Transplant for Immunoglobulin Light Chain Amyloidosis Patients Aged 70 to 75. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 2157-2159 | 4.7 | 3 |
| 14 | Utility and prognostic value of 18F-FDG PET/CT scan in patients with newly diagnosed multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 8023-8023 | 2.2 | |
| 13 | Bortezomib, Lenalidomide and Dexamethasone (VRD) Followed By Autologous Stem Cell Transplant for Newly Diagnosed Multiple Myeloma; The Mayo Clinic Experience. <i>Blood</i> , 2018 , 132, 2147-2147 | 2.2 | |
| 12 | Plasma Cell Disorders in Patients with Age-Related Transthyretin (ATTRwt) Amyloidosis. <i>Blood</i> , 2018 , 132, 5610-5610 | 2.2 | |
| 11 | Three Decades of Autologous Stem Cell Transplantation for Myeloma; Trends in Early Mortality and Survival. <i>Blood</i> , 2018 , 132, 3436-3436 | 2.2 | |
| 10 | T Cell Large Granular Lymphocytic Leukemia and Co-Existing Plasma Cell Disorders. <i>Blood</i> , 2018 , 132, 5368-5368 | 2.2 | |
| 9 | Plasma Cell Proliferative Index Is an Independent Predictor of Progression in Smoldering Multiple Myeloma. <i>Blood</i> , 2018 , 132, 3160-3160 | 2.2 | 2 |
| 8 | Therapy for relapsed multiple myeloma. <i>Panminerva Medica</i> , 2018 , 60, 174-184 | 2 | 1 |

| | | | |
|---|--|-----|----|
| 7 | Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1323-1329 | 2.2 | 68 |
| 6 | Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma. <i>Blood Cancer Journal</i> , 2018 , 8, 106 | 7 | 13 |
| 5 | Venetoclax for the treatment of multiple myeloma. <i>Expert Review of Hematology</i> , 2018 , 11, 915-920 | 2.8 | 18 |
| 4 | Utility and prognostic value of F-FDG positron emission tomography-computed tomography scans in patients with newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2018 , 93, 1518-1523 ¹ | 7.1 | 15 |
| 3 | Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation. <i>Blood Advances</i> , 2018 , 2, 769-776 | 7.8 | 16 |
| 2 | Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma. <i>Blood Advances</i> , 2018 , 2, 3149-3154 | 7.8 | 17 |
| 1 | Prognostic Significance of Stringent Complete Response after Stem Cell Transplantation in Immunoglobulin Light Chain Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 2360-2364 ¹ | 4.7 | 13 |